• “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>Biosensors收购Spectrum Dynamics

    扬州万福路快速路新址: Biosensors收购Spectrum Dynamics

    Biosensors International2013年5月24日 16:43 点击:2073

    时时彩网络平台 www.qlgr.net Biosensors International  

    2013年5月16日 新加坡Biosensors International完成收购Spectrum Dynamics公司


     Spectrum Dynamics是一家领先的医疗器械公司,已经开发出一种具有创新性的高清晰度功能的成像技术,提供高速,高分辨率核医学影像,以更好地满足临床和工作流程这个快速增长的市场需求。

    Biosensors to Acquire Assets of Spectrum Dynamics

    Interventional Cardiology Pioneer Aims to Offer Improved Detection of Cardiovascular Disease

    SINGAPORE, May 16, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced onMay 13, 2013 that it has entered into an agreement to acquire substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions, subject to the fulfillment of certain conditions.

    Founded in 2004, Spectrum Dynamics is a privately held medical imaging and clinical applications company that has developed innovative technology providing high-speed, high-resolution functional 3D images to help physicians determine the most appropriate treatment for their patients.

    Used by leading medical centers around the world, Spectrum Dynamics' revolutionary D-SPECT Cardiac Imaging System lays the foundation for its next-generation cardiac clinical protocols that will provide new diagnostic information and treatment strategies to interventional cardiologists.

    Spectrum Dynamics has more than 70 issued and pending patents. It is ISO-certified and its products have been approved for sale in major markets including the US, Japan, Europe and Canada. Additional approvals in other key markets are pending.

    "We are very excited about becoming a part of Biosensors' growing family. The synergy created as a result of this deal will provide us with meaningful resources to better realize the potential of our business," said Prof. Shlomo Ben-Haim , Co-Founder and Chairman of Spectrum Dynamics. "The ability to accurately detect and diagnose reversible ischemia prior to catheterization has become a critical issue in the treatment of cardiovascular disease. Spectrum Dynamics' advanced imaging systems will enable doctors to more effectively determine the appropriate course of treatment for their patients. By combining the sales forces of the two companies, Biosensors can provide extensive coverage and leverage their excellent relationships with key potential customers in order to drive the use of Spectrum Dynamics' technology worldwide."

    The deal consideration is approximately US$51 million, with potential earn-out payments upon fulfilling certain performance criteria. Under the terms of the deal, the two companies will also create a joint venture aimed at developing future non-cardiac applications. Biosensors expects the transaction to have minimal impact on its 2014 fiscal year financial results, with the potential to be moderately accretive to its earnings in the following fiscal year.

    "Similar to Biosensors, Spectrum Dynamics is a pioneer in its field and has a proven business model, with products being used by leading medical institutions and teaching hospitals in the US, Europe and Japan. We will build on Spectrum Dynamics' initial success, as it has huge potential to expand both in new geographical locations and in various application protocols. We believe these innovative applications can offer patients more advanced treatments and, at the same time, help physicians and hospitals reduce the time and money they need to spend on making accurate diagnoses," commented Biosensors' CEO Dr. Jack Wang . "Additionally, hospitals and physicians in the emerging markets will thus be able to screen cardiac patients more expediently and serve more patients in a given time. This acquisition is in line with our strategic objective to expand our product offerings. It also reflects our commitment to continue diversifying our business as we take our company to the next level."

    About Biosensors International Group, Ltd.

    Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

    With the increasing use of the BioMatrix™ family of drug-eluting stents and the recent launch of our Axxess™ self-expanding bifurcation drug-eluting stent, we are rapidly emerging as a leader in the global coronary stent market. The development of the BioFreedom™ drug-coated stent will further reinforce our market position.

    All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer-free stent abluminally coated with BA9, has recently received CE Mark Approval.

    For more information, please visit www.biosensors.com.

    About Spectrum Dynamics

    Spectrum Dynamics LLC is a pioneering medical device company focused on personalized molecular imaging and applications. Spectrum Dynamics aims to revolutionize the practice of nuclear cardiology, and eventually all nuclear medicine applications, by dramatically enhancing workflow and providing new clinical applications not possible with conventional technology.

    For more information, please visit www.spectrum-dynamics.com

    Forward-Looking Statements

    Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

    For further information, please contact:

    Biosensors Investor Relations 
    Wong Teck Yenn 
    Biosensors International Group 
    +65-6213-5777 
    [email protected]

     

    SOURCE Biosensors International Group, Ltd.



    RELATED LINKS
    //www.biosensors.com/
    //www.spectrum-dynamics.com/

    (来源: Biosensors International )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 河北福彩好运彩3基本走势 彩票开奖结果 河南省泳坛夺金走势图 彩票360排列三走势图 广东11选5限行规则 盛京棋牌网南通棋牌 0809法甲瑙 海南七星彩预测 深圳风采搅珠颜色 北京幸运28彩票 足彩4场进球18136期 平码王三中三资料 福建31选7开奖走势图 六合图库图纸印刷网 大乐透投注算法公式